ALYREF and adrenal cortex carcinoma: Notably, ALYREF demonstrated a significant correlation with CD276, an immunoglobulin superfamily member involved in regulating T-cell-mediated immune responses, in patients with urinary tumors (KICH, KIRP, KIPAN, PRAD, BLCA, and ACC), LIHC, GBMLGG, and LGG, especially in ACC, KIPAN, KIRP, PRAD, LIHC, GBMLGG, and LGG (r ≥ 0.5) (Fig. 2e).